

Claims

1. Compound for use in the treatment of a human subject suffering from cerebrovascular accident (CVA) wherein the compound is a selective human MelanoCortin-1-Receptor (hMC-1-R) and human MelanoCortin-4-Receptor (hMC4R) agonist.
- 5 2. Compound for use according to claim 1, wherein the hMC1R and hMC4R agonist of the invention is Blood-Brain-Barrier (BBB) permeable.
3. Compound for use according to claim 1, wherein the compound is selected from afamelanotide, a pharmaceutically acceptable salt of afamelanotide, bremelanotide, a pharmaceutically acceptable salt of bremelanotide and mixtures thereof.
- 10 4. Compound for use according to claims 1-3, wherein the compound is afamelanotide or a pharmaceutically acceptable salt thereof.
5. Compound for use according to claims 1-3, wherein the compound is bremelanotide or a pharmaceutically acceptable salt thereof.
6. Compound for use according to claims 1-5, wherein the compound is administered in the form of
15 an injectable.
7. Compound for use according to any one of claims 1-6, wherein the compound is administered in an immediate or controlled release injection.
8. Compound for use according to any one of claims 1-7, wherein the compound is injected subcutaneously.
- 20 9. Compound for use according to any one of claims 1-8, wherein the compound is administered with a dose of from 0.0007 to 1.5mg/kg/day for at least 1 day, wherein kg represents the weight of the human subject in kilograms.
10. Compound for use according to any one of claims 1-9, wherein the compound is administered at a dose of from 0.05 to 100mg.
- 25 11. Compound for use according to any one of claims 1-10, wherein the subject suffers from ischemic CVA (AIS) and/or hemorrhagic CVA.

12. Compound for use according to any one of claims 1-11, wherein the human subject is treated with a tissue plasminogen activator (tPA) and subsequently or prior treated with the compound wherein the compound is selected from afamelanotide, a pharmaceutically acceptable salt of afamelanotide, bremelanotide, a pharmaceutically acceptable salt of bremelanotide and mixtures thereof.
13. Compound for use according to any one of claims 1-12, wherein afamelanotide is administered as a subcutaneously administered 16mg implant on day 0 and on day 1.
14. Method of treatment of a human subject suffering from cerebrovascular accident (CVA), wherein the human subject is treated with a compound is selected from afamelanotide, a pharmaceutically acceptable salt of afamelanotide, bremelanotide, a pharmaceutically acceptable salt of bremelanotide and mixtures thereof.
15. Use of afamelanotide, a pharmaceutically acceptable salt of afamelanotide, bremelanotide, a pharmaceutically acceptable salt of bremelanotide and mixtures thereof for the manufacturing of a medicament for the treatment of a human subject suffering from cerebrovascular accident (CVA).